Combo Immunotherapy in NSCLC: Not These Two Drugs Combo Immunotherapy in NSCLC: Not These Two Drugs
Pembrolizumab monotherapy remains a standard of care, after trial results show that adding ipilimumab conveys no benefits but incurs greater toxicity.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
More News: Cancer & Oncology | Hematology | Immunotherapy | Non-Small Cell Lung Cancer | Toxicology | Yervoy